0001127602-18-035030.txt : 20181203
0001127602-18-035030.hdr.sgml : 20181203
20181203201329
ACCESSION NUMBER: 0001127602-18-035030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181130
FILED AS OF DATE: 20181203
DATE AS OF CHANGE: 20181203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Piacquad David
CENTRAL INDEX KEY: 0001602343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 181215228
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2018-11-30
0000318154
AMGEN INC
AMGN
0001602343
Piacquad David
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
1
SVP, Business Development
Common Stock
2018-11-30
4
M
0
6500
54.69
A
45128
D
Common Stock
2018-11-30
4
F
0
4109
202.37
D
41019
D
Nqso (Right to Buy)
54.69
2018-11-30
4
M
0
6500
0
D
2013-04-25
2021-04-25
Common Stock
6500
0
D
Non-market exercise of 6,500 stock options expiring April 25, 2021 wherein 4,109 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 357 RSUs which vest in one installment on 1/30/2019; 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 136 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.
/s/ David A. Piacquad
2018-11-30